

**Bradley A. Alford** has been a director of Perrigo since 2017. Mr. Alford currently serves as a director for Avery Dennison Corporation and previously served as director for Conagra Brands, Inc. and Nestlé USA

Mr. Alford's previous work experience includes serving as an Operating Partner at Advent International Corporation (a global private equity firm) from 2016-2021; an Industry Advisor for Advent International Corporation from 2014-2016; and as the Chairman and CEO of Nestlé USA (a multinational food and beverage company) from 2006-2013. He has extensive public and private sector industry knowledge and experience in management, operations and supply chain as well as the development and marketing of consumer products.

**Orlando D. Ashford** has been a director of Perrigo since 2020 and Chair of the Board since 2022. Mr. Ashford currently serves as the Chief People Officer at Fanatics Holding Inc. (a global sporting company) since 2022. Mr. Ashford currently serves as a director for Array Technologies, Inc. and previously served as a director at ITT, Inc.

Previously Mr. Ashford served as Executive Chairman of Azamara Cruise Lines (a worldwide cruise line company) from 2021-22; President of Holland America Line (a worldwide cruise line company) from 2014-2020; and Strategic Advisor at Sycamore Partners (a private equity firm) from 2020-2021. He has extensive private and public company leadership expertise and has over 30 years of global experience in executive management, talent management, organizational development, change management and corporate human resources. Mr. Ashford also has vast experience planning and executing change initiatives and enabling successful strategy execution for organizations.

**Julia M. Brown** has been a director of Perrigo since 2023. Ms. Brown currently serves a director for Ocado plc, Molson Coors Beverage Company and Solo Brands. She previously served as a director for Honest Company.

Ms. Brown's previous work experience includes serving as Chief Procurement & Sustainability Officer for Mars Wrigley (a world leading manufacturer of chocolate and confectionary) from 2020-2021; and Chief Procurement Officer for Carnival Corporation & plc (the world's largest global cruising company) for 2015-2020. Ms. Brown has extensive management experience across the consumer and hospitality sectors and deep expertise in areas of organization and business transformation, sourcing, supply chain, external manufacturing, operations optimization, enterprise risk management, sustainability and M&A. With her extensive public company board and advisory experience, Ms. Brown provides beneficial insight on matters of global executive management, governance, risk management and human capital.

**Katherine C. Doyle** has been a director of Perrigo since 2020. Ms. Doyle currently serves as Executive Advisor to private equity firms that invest and grow in consumer healthcare and technology businesses. Ms. Doyle currently serves as a director for Ahold Delhaize and was previously a director for Bemis Company Inc.

Formerly Ms. Brown served as Chief Executive Officer for Swanson Health Products (a leading global e-commerce health and wellness company) from 2016-2019; Senior Vice President, Abbott Laboratories, Nutritional Products Division (a global healthcare company) from 2011-2014; and Principal at McKinsey & Company (a global management consulting firm) from 1993-2010. Ms. Doyle has 30 years of experience in management, operations, sales and marketing of consumer health products and brings a wealth of experience and knowledge in both US and European retail channels with depth in e-commerce. Her experience also includes corporate strategy and portfolio management.

**Adriana Karaboutis** has been a director of Perrigo since 2017. Ms. Karaboutis currently serves as a director for Savills plc and AON plc. Formerly she served as a director for Aspen Technology, Advance Auto Parts Inc and Blue Cross Blue Shield of Massachusetts

Ms. Karaboutis previous work experience includes: serving as Group Chief Information & Digital Officer at National Grid (a multinational energy/utility company) from 2017-2023; Executive Vice President at Biogen Inc. (a global biotechnology company) from 2014-2017; Vice President and Global Chief Information Officer at Dell inc. (a global services and technology company) from 2010-2014; and multiple leadership roles in international and cross-functional technology, manufacturing and supply chain at Ford Motor Company and General Motors from 1989-2010.

Ms. Karaboutis has extensive management experience across multiple sectors and regulated business including automotive, technology, cybersecurity, healthcare, biotechnology, retail and consumer packaged goods. She has a deep understanding in key areas of digital transformation, data sciences, production planning, supply chain optimization, cybersecurity and corporate affairs. Her extensive public company board experience provides valuable perspective on matters of risk oversight, corporate governance and executive management.

**Jeffrey B. Kindler** has been a director of Perrigo since 2017. Mr. Kindler is currently the CEO for Centrexion Company (a biopharmaceutical company) since 2013. He is also a Senior Advisor for Blackstone Group (the world's largest alternative asset manager) since 2020. Mr. Kindler is currently a director for Terns Pharmaceutical, Lupin Pharmaceuticals and Precigen. He was formerly a director for PPD, vTv Therapeutics and Siga Technologies as well as a Venture Partner at Artis Ventures (a venture fund focused on life-sciences companies).

Mr. Kindler is an experienced healthcare executive, investor and advisor holding leadership positions at General Electric, McDonald's and Pfizer. He brings substantial expertise in pharmaceutical, healthcare and retail sectors. He has a deep understanding of multinational corporate matters including regulation, litigation, compliance, crisis management, brand, franchise management, executive leadership, and M&A.

**Patrick Lockwood-Taylor** has been a director of Perrigo since 2023. Mr. Lockwood-Taylor is currently the President and Chief Executive Officer for Perrigo plc since 2023. Mr. Lockwood Taylor currently serves as a director for Bush Bros. LLC.

Formerly, Mr. Lockwood-Taylor was the President at Bayer USA from 2020-2023 and was the Regional President of Consumer Health North America for Bayer AG (a multinational pharmaceutical and biotechnology company) from 2018-2020. He served as the President and Chief Executive Officer for the Oneida Group, Inc (the largest supplier of dinnerware to the food service industry in North America) from 2016-2018. Prior to that Mr. Lockwood-Taylor served in multiple international leadership roles within Proctor & Gamble (an American multinational consumer good corporation) from 1991-2016. Mr. Lockwood-Taylor has held executive leadership roles within both the private and public sectors with over 25 years of experience in global leadership roles including operation management, sales, marketing, country management, brand franchise leadership and general management. He also has extensive experience in strategic planning and direction, brand building, and customer relationships.

**Albert A. Manzone** has been a director of Perrigo since 2022. Mr. Manzone is currently the Deputy Chief Executive Officer at Monte-Carlo Society des Bains de Mer (a leader in luxury hospitality) since 2023. Mr. Manzone also serves as a director at Syntec Optics and FL Entertainment.

Previously Mr. Manzone was the Chief Executive Officer and Director at Whole Earth Brands (a global food company) from 2016-2023. In addition, Mr. Manzone was the European President at Oettinger Davidoff AG (a luxury goods company) from 2012-2016. Prior to this position, Mr. Manzone held multiple US and international executive and leadership roles at Haleon (fka Novartis Consumer Health), W.M. Wrigley Jr. Company, PepsiCo and McKinsey & Company from 1993-2012. Mr. Manzone has over 30 years of experience creating value in the hospitality, luxury, entertainment, food and beverage and consumer health sectors. He has a proven track record developing private and public companies into top performers through strategic vision, operational excellence, M&A, and building teams. Mr. Manzone has strong executive leadership skills and has extensive global experience across all continents.

**Donal O'Connor** has been a director of Perrigo since 2014. Mr. O'Connor currently serves as a director for Theravance Biopharma Inc. and is the Chairman at Huttonread. He is also the Chairman at Glaco Steel Ltd. (Ireland's leading steel galvanizing company) since 2010. Mr. O'Connor was previously a director for Malin Corporation plc and Elan Corporation plc.

Mr. O'Connor has extensive financial management, accounting and auditing expertise, as well as valuable experience in working with regulators and government. He was previously a member of the Irish Auditing and Accounting Supervisory Board and the PwC Global Board. Mr. O'Connor has chaired the PwC Eurofirms Board as well as being the named Territory Senior Partner of PwC Ireland. Mr. O'Connor has executive leadership experience for both private and public corporations.

**Geoffrey M. Parker** has been a director of Perrigo since 2016. Mr. Parker is currently the Executive Vice President and Chief Financial Officer at Allogene Therapeutics, Inc. (a biotechnology company) since 2023. Mr. Parker has served as a director for Better Therapeutics, ChemoCentryx, Genomic Health, and Sunesis Pharmaceuticals.

Previously he was the Chief Operating Officer & Chief Financial Officer at Tricida, Inc. (a biotechnology company) from 2017-2023. He was the Chief Financial Officer at Anacor Pharmaceuticals, Inc. (a biotechnology company) from 2010-2015 and prior to this position he was a Managing Director and Partner for Healthcare Investment Banking, Goldman Sachs (a multinational investment bank and financial service company) from 1997-2009.

Mr. Parker has extensive experience as a senior executive at multiple biotechnology companies and a board member to multiple healthcare companies. He brings unique understanding of trends in the healthcare industry including experience with emerging technologies and regulatory strategies. He also provides valuable perspective on areas of financial management and capital allocation. He has extensive capital markets and M&A experience.

## *Director Compensation*

### Chairman of the Board

Annual Cash Retainer: \$150,000

Equity Compensation: \$375,000

Director Annual Cash Retainer: \$75,000

Committee Member Retainer: Audit \$12,500

Remuneration \$12,500

Nominating & Governance \$8,000

Committee Chair Retainer: Audit \$25,000

Remuneration \$25,000

Nominating & Governance \$16,000

Director Equity Compensation: \$300,000